696574-58-0

Basic information

• Product Name: 1H-Purin-6-amine, 8-[(3-methoxyphenyl)thio]-
• CAS NO: 696574-58-0
• Molecular Formula: C12H11N5OS
• Molecular Weight: 273.318
• Mol File: 696574-58-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1H-Purin-6-amine, 8-[(3-methoxyphenyl)thio]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Purin-6-amine, 8-[(3-methoxyphenyl)thio]-(696574-58-0)
• EPA Substance Registry System: 1H-Purin-6-amine, 8-[(3-methoxyphenyl)thio]-(696574-58-0)

Safety Data

• Hazardous Substances Data: 696574-58-0(Hazardous Substances Data)

Upstream product

• 7390-62-7 6-amino-7,9-dihydro-8H-purine-8-thione 
• 766-85-8 3-methoxy-1-iodobenzene 
• 66224-66-6 adenine 
• 15570-12-4 3-methoxybenzenethiol 
• 6974-78-3 8-bromoadenine 
• 7390-62-7 8-mercaptoadenine 

Downstream Products

• 827302-49-8 C₃₅H₃₀N₅O₃PS 
• 827302-48-7 C₃₅H₃₀N₅O₂PS 
• 827302-47-6 C₃₅H₃₄N₅O₄PS 
• 827302-45-4 C₃₄H₃₂N₅O₃PS 
• 827302-46-5 C₃₅H₃₄N₅O₃PS 
• 827302-44-3 C₃₄H₃₂N₅O₂PS 
• 521308-36-1 9-butyl-8-(3-methoxy-phenylsulfanyl)adenine 
• 852030-31-0 8-(3-methoxy-phenylsulfanyl)-9-pent-4-ynyl-9H-purin-6-ylamine 
• 852030-51-4 9-(2-isopropoxy-ethyl)-8-(3-methoxy-phenylsulfanyl)-9H-purin-6-ylamine 
• 827302-38-5 C₃₄H₃₂N₅OPS 
• 827302-40-9 C₃₅H₃₀N₅OPS 
• 827302-39-6 C₃₅H₃₄N₅O₂PS 

Relevant articles and documents

Preparation of 8-(arylsulfanyl)adenines with diazonium salts under mild, aerobic conditions

(Chemical Equation Presented) 8-(Arylsulfanyl)adenines 11 were prepared in up to 75% yield by reacting the 8-thionoadenine 6 (acetic acid 3-(6-amino-8-thioxo-7,8-dihydropurin-9-yl)propyl ester) with benzenediazonium tetrafluoroborates in DMSO. Benzenediazonium ions carrying an electron-withdrawing substituent gave the highest yields. The reaction proceeded smoothly at room temperature without any base and could be performed under air atmosphere. The extremely mild conditions are compatible with a wide range of functional groups.

HSP90 Inhibitors Containing a Zinc Binding Moiety

The present invention relates to HSP90 inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.